February 2026 Research Update

This month, studies on diagnosis mostly pointed in the same direction: once ATTRwt cardiac amyloidosis is on the radar, noninvasive tools can often confirm it, and researchers are trying to tighten the rules for what counts as "early" disease. The main message is not that one test replaces the others, but that more precise imaging measurements and clearer definitions may reduce missed or late diagnoses. The evidence is still mostly from single centers or small groups, so these ideas need broader testing before they can be treated as universal.

Two echocardiography studies suggest that looking beyond a single "thick wall" cutoff may matter, especially for women. In one small ATTRwt group, septal wall thickness of 12 mm or more was common in men but missed a substantial portion of women, while a sex-specific left ventricular mass index cutoff captured all women in that cohort. [1]

A separate prospective study in older adults with wild-type ATTR suggested a specific regional strain change (basal inferoseptal strain) may flag early heart involvement among people who already had ATTR deposits found in carpal tunnel tissue. In that study, this regional measurement separated groups linked to heart involvement better than global strain or ejection fraction when compared against troponin-T elevation. [2]

Imaging work also explored ways to make existing scans easier to interpret or useful in special situations. A retrospective study reported that a SPECT-only approach guided by a chest X-ray produced a cardiac-to-contralateral ratio that separated ATTR-CM from non-ATTR-CM extremely well in their 90-patient dataset. [3]

In a very small case series mainly about hereditary ATTR variants, PiB PET/CT detected cardiac uptake in several patients whose bone scans were negative, but PiB PET/CT was negative or inconclusive in the patients who had positive bone scans. This points to a possible role for PET in certain variant types where standard bone scanning is less sensitive, but it does not yet show how useful this would be for typical ATTRwt care. [4]

Beyond tests, one survey of 118 Czech patients described the real-world "diagnostic journey": the longest delay was usually from first symptoms to someone suspecting cardiac amyloidosis, while confirmation after suspicion was relatively quick and often noninvasive. Many patients were diagnosed at earlier functional stages (NYHA I or II), even though misdiagnosis before the correct diagnosis was common. [5]

A narrative paper argued that "early diagnosis" in ATTRwt is inconsistently defined across studies and proposed a practical definition based on being in NYHA class I, having NT-proBNP 500 pg/mL or less, and not using diuretics. The paper did not provide outcome data for this definition, so its usefulness remains a research question until validated in routine care. [6]

For patients and caregivers, this group of studies mainly adds clarity about why diagnosis can still be delayed and what researchers are trying to improve. The survey suggests that the biggest bottleneck may be getting ATTRwt-CM suspected in the first place, while confirmation can often be done without a heart biopsy once suspicion is raised. The echo and scan studies are early steps toward more consistent and possibly fairer detection (including attention to sex differences), but they do not yet prove that any single cutoff or newer imaging approach should be used everywhere.

What remains uncertain is how well these proposed measurements and definitions work across different hospitals, scanners, and patient groups, and whether they lead to better long-term outcomes when applied broadly. For now, this month mostly strengthens the research push toward earlier recognition and more standardized diagnostic language, rather than changing what any one person should expect from routine testing. [1] [2] [3] [4] [5] [6]

This month, the observational studies added a clearer picture of factors that can travel with ATTRwt cardiomyopathy and may signal higher risk, even without dramatic symptoms. The findings were not about new treatments, but about recognizing which accompanying conditions or exposures may mark a different course. Because these are observational results, they describe patterns seen in groups rather than proving what causes what.

In the DIAMOND registry sub-study, only a minority of ATTRwt-CM patients had a history of acute coronary syndrome (9%), but that history was linked to a higher risk of adverse outcomes. Obstructive coronary artery disease without a prior acute coronary syndrome did not show the same increased risk in this analysis. [7]

A Danish registry study compared 258 ATTRwt-CM patients with matched general-population controls and found higher exposure to upper-body mechanical workload and more agricultural employment among ATTRwt-CM patients. The same study also reported higher 3-year cardiovascular and overall mortality in the ATTRwt-CM group than in controls, but it could not determine whether work exposures contributed directly to amyloid disease. [8]

A small controlled study of autonomic testing found that people with ATTRwt cardiomyopathy showed measurable problems in heart-related autonomic responses even though they did not report more autonomic symptoms than healthy controls. Differences showed up in blood pressure and heart rate responses during standing/tilt and in Valsalva-related measures, while sweat testing looked similar between groups. [9]

A separate systematic review looked at heart failure populations rather than confirmed ATTRwt cohorts, and it estimated that cardiac amyloidosis is found in about 10% of people with heart failure, with ATTRwt making up most of those amyloidosis diagnoses. The review also reported that about 24% of cardiac amyloidosis cases were in females, while results varied widely between studies and regions. [10]

For patients, these studies help explain why ATTRwt-CM can look different from person to person and why "silent" body changes can exist alongside mild symptoms. The autonomic testing results may matter later if confirmed, because they suggest some people could have body-control changes (blood pressure and heart rate responses) that are not obvious day to day. The coronary syndrome and occupational-history findings may matter now mainly as context for prognosis research, not as proof that one event or one job type causes ATTRwt.

What remains uncertain is how these patterns should be used in individual care, since the studies do not test interventions and cannot separate cause from correlation. The heart failure meta-analysis supports the idea that amyloidosis is not rare within heart failure, but the wide variation between studies means local rates may differ. Taken together, this month adds to the bigger picture of ATTRwt as a condition where co-existing heart disease history, lifetime exposures, and nervous system effects may all contribute to the overall experience and risk profile. [7] [8] [9] [10]

Two very different studies still connect to a shared patient-relevant idea: how confidently we can identify ATTRwt in data and how consistent the underlying amyloid structure may be. One strengthens the reliability of research that uses national health registries, and the other supports the concept that many ATTR forms share a common fibril "shape." Both are building blocks that may support better future studies rather than changing daily care now.

In Denmark, a medical-record validation study found that registry diagnosis codes for amyloidosis were usually correct, with particularly strong performance for ATTRwt when patients were older and identified in cardiology settings. In practical terms, this suggests that some large registry studies may be more trustworthy for ATTRwt than for hereditary ATTR, which had lower accuracy in this dataset. [11]

A laboratory-based cryo-EM study examined heart amyloid fibrils taken from patients with three neuropathy-associated ATTR variants and found that all shared a common amyloid core that has also been seen in ATTRwt and most cardiac hereditary ATTR. This supports the idea that different ATTR mutations can still produce a similar core structure in the heart, which could matter for future structure-guided diagnostic approaches. [12]

For patients and caregivers, the registry validation study matters because it affects how much confidence we can place in large real-world reports about ATTRwt incidence, outcomes, and health-care use. The cryo-EM structural work is earlier-stage research, but it helps clarify that ATTRwt and many hereditary ATTR forms may share a conserved amyloid core in the heart, which could support future diagnostic tools that depend on recognizing a consistent structure.

What remains uncertain is how quickly these pieces translate into patient-facing changes. Registry coding accuracy can vary by country and hospital systems, and the structural study looked at a very small number of samples and did not test a new clinical test. For now, these studies mostly strengthen the foundation for better research and more standardized diagnostics in the future. [11] [12]

This month included two case reports that broaden the range of how ATTRwt can present and how intensively it can be evaluated. They do not establish what is typical, but they illustrate situations where ATTRwt was linked to findings outside standard expectations or where specialized testing revealed hidden heart stiffness. The common takeaway is that ATTRwt can involve more than symptom severity alone might suggest in a single individual.

One report described a man with ATTRwt-CM who had relatively mild symptoms, yet combined PET-MR imaging and invasive pressure-volume testing showed substantial amyloid involvement and diastolic dysfunction (stiffness) in both ventricles. The authors presented this as supporting early tafamidis use in that individual, but the report cannot show whether earlier treatment changes outcomes for others. [13]

A second report described an older man with ATTRwt who developed organizing pneumonia, and a lung biopsy showed transthyretin amyloid deposits alongside the pneumonia pattern. After corticosteroid treatment, the lung infiltrates partially improved, but this single case does not define how often ATTRwt affects the lungs or what the best approach is. [14]

For patients, these reports mainly add awareness that ATTRwt can occasionally be connected with less common organ findings or with heart dysfunction that is not obvious from symptoms alone. The advanced imaging and invasive testing in one case shows the kind of detailed evaluation that can be done in research-level or specialized settings, but it is not routine practice. The lung case highlights that amyloid deposits can sometimes be found outside the heart in ATTRwt, although how often this happens remains unclear.

Because case reports involve 1 person, they are best seen as examples rather than expectations. They may help researchers and clinicians recognize unusual patterns to study, but they do not provide general predictions about risk, screening, or treatment response for the broader ATTRwt community. [13] [14]